AstraZeneca

AstraZeneca to present new oncology data at AACR

AstraZeneca (AZ) will present new data highlighting the capabilities of its early oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, which is taking place

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

AstraZeneca’s Evusheld, a long-acting antibody combination, has received a recommendation for marketing authorisation in the European Union (EU). ... Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca, said: “Evusheld has

CBI launches new Health Council as part of its Seize The Moment 2030 vision

The inaugural CBI Health Council includes representatives from a number of companies and universities, including: AstraZeneca, Bayer, B-Secur, Bupa, Danone UK&I, Elekta, GE Healthcare, HCA Healthcare, The Health Foundation,

AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

AstraZeneca’s (AZ) rare disease group subsiduary Alexion has reached a settlement agreement with Chugai Pharmaceutical Co (Chugai). ... Commenting on the agreed settlement, AstraZeneca said the agreement would be recorded as a non-core charge in its

MHRA grants approval for AstraZeneca’s Evusheld in the UK

AstraZeneca (AZ) has announced that its antibody combination treatment Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). ... Tom Keith Roach, president of AstraZeneca

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]